For stock trading, rely on Jinlin Analyst Research Reports — authoritative, professional, timely, and comprehensive, helping you uncover potential thematic opportunities! The 64-year-old president of Harbin Pharmaceutical Group Co., Ltd. (600664.SH) has been placed under detention, having earned over 2.96 million yuan last year and once served as chairman of Sanjing Pharmaceutical; the company's stock price once rose 200% in 30 trading days, with net profit up 58% in the first half of the year.

On October 11, according to Hongxing Capital Bureau, Harbin Pharmaceutical Group Co., Ltd. (600664.SH) today issued an announcement stating that it had recently received a "Notice of Case Filing" and a "Notice of Detention" from the relevant supervisory commission regarding the company's director and president, Lu Chuanyou. At present, the company has made proper arrangements for the relevant work. The company's chairman, other directors, and senior management personnel are all performing their duties normally, the board of directors is operating normally, and production and operations are normal. The announced matter will not have a material impact on the company's production, operations, and management.

According to public information, Harbin Pharmaceutical Group Co., Ltd. (600664.SH) listed on the Shanghai Stock Exchange in June 1993 and was the first listed company in China's pharmaceutical industry. Its main businesses include pharmaceutical research and development and manufacturing, as well as wholesale and retail operations. Brands such as "Harbin Pharmaceutical," "Sanjing," and "Gaizhonggai" are familiar to the public. According to the company's annual report, Lu Chuanyou was born in 1962 and holds a master's degree. He previously served as chief engineer and factory director of Harbin Pharmaceutical Group Pharmaceutical Factory No. 6, and as chairman and general manager of Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd. He currently serves as a director and president of the company's 10th board of directors, with a term from December 2023 to December 2026. In 2025, the total pre-tax remuneration Lu Chuanyou received from the company was 2.9668 million yuan. In addition, Lu Chuanyou also serves as the legal representative of Harbin Pharmaceutical Group Co., Ltd. (600664.SH). The company's 2026 semi-annual report shows that company head Lu Chuanyou, accounting work supervisor Meng Xiaodong, and accounting institution head Yu Guo declared and guaranteed the authenticity, accuracy, and completeness of the financial report in the semi-annual report.

In the second half of this year, Harbin Pharmaceutical Group Co., Ltd. (600664.SH) experienced a rapid rise, and for the full year its stock price has risen more than 114%. Starting in July this year, the stock continued to climb. From July 1 to August 31, the stock price cumulatively rose more than 205%; on September 23, it touched the year's highest intraday price of 9.86 yuan per share. After that, it began to fluctuate downward. On October 9, Harbin Pharmaceutical Group Co., Ltd. (600664.SH) closed up 2.07% at 7.39 yuan per share, with a total market value of 18.6 billion yuan. During this period, Harbin Pharmaceutical Group Co., Ltd. (600664.SH) issued six announcements on abnormal stock trading fluctuations. An announcement on August 21 showed that as of the close on August 20, 2026, the cumulative deviation of the company's daily closing price increase over 30 consecutive trading days had reached 200%; the company's stock price had risen sharply in the short term, significantly higher than the Shanghai Composite Index and the industry in which it operates, and recent turnover had increased noticeably compared with the past. At present, trading risks are relatively high, and there is a risk of rapid decline. The production and operations of the company's two major business segments, pharmaceutical industry and pharmaceutical commerce, are normal, and the main business has not changed.

In terms of performance, Harbin Pharmaceutical Group Co., Ltd. (600664.SH) achieved revenue of 15.964 billion yuan in 2025, a year-on-year decrease of 1.31%; net profit attributable to the parent company was 362 million yuan, a year-on-year decrease of 42.50%. In the first half of 2026, the company achieved operating revenue of 8.296 billion yuan, a year-on-year increase of 2.10%; net profit attributable to the parent company was 410 million yuan, a year-on-year increase of 57.99%.